PHASE IIb DATA PRESENTATION

JOIN MAILING LIST

PIPELINE

INVESTORS

VIDEO

ABOUT US

Oramed Pharmaceuticals (NASDAQ: ORMP) has developed an innovative technology to transform injectable treatments into oral therapies.

Oramed’s flagship product, an oral insulin capsule, has the potential to better the lives of millions of diabetics around the world – allowing, amongst other things, type 2 patients to begin insulin therapy earlier without fear of needles.

Oramed’s oral insulin is currently in advanced clinical trials under the US FDA for both type 1 and type 2 diabetes.

In addition to oral insulin, the company’s proprietary POD™ technology can be used to orally administer a number of protein-based therapies, which are available only via injection.

PRESS RELEASES

Oramed Reports Additional Phase IIb Oral Insulin Study Data Demonstrating Significant Lowering of Glucose Levels vs Placebo

July 28th, 2016|

JERUSALEM, July 28, 2016 /PRNewswire/ —

Statistically Significant Results Across Key […]

Oramed Appoints Dr. Roy Eldor as Chief Medical Director

July 26th, 2016|

JERUSALEM, July 26, 2016 /PRNewswire/ —

Oramed Pharmaceuticals Inc. (NASDAQ: ORMP) (http://www.oramed.com), […]